0001104659-26-059816
SEC filingQ1 2026 delivered stable $109.2M revenue amid BMS collaboration normalization, with operating losses reflecting portfolio prioritization impacts and personnel reductions, partially offset by higher facility costs. Cash burn improved meaningfully due to smaller working capital changes.
Century Therapeutics reported $109.2 million in revenue for Q1 FY2026, matching Q1 FY2025 levels exactly. This stability stems from the complete amortization of the remaining Bristol-Myers Squibb collaboration transaction price in the prior-year period, following the agreement's termination effective March 12, 2025. The change in operating assets and liabilities included a $109.2 million decrease in deferred revenue tied directly to this termination, signaling a return to pre-collaboration revenue dynamics. Investors should view this flatness not as stagnation but as normalization, with no future BMS milestones or royalties expected. The company now focuses on advancing its iPSC-derived therapies for autoimmune diseases and cancer, where product sales remain several years out pending clinical progress.
Operating income deteriorated to a $23.7 million loss from $74.2 million profit YoY, yielding a -21.7% operating margin. This swing reflects the absence of prior-period collaboration gains alongside elevated R&D and operational costs. A key driver was the portfolio prioritization announced in Q3 2025, which reduced personnel expenses and remeasured contingent consideration liabilities, though partially offset by increases in facility and allocated costs. These dynamics include personnel, laboratory, and indirect facility expenses, underscoring disciplined cost management amid a leaner operation. Net income followed suit at -$21.6 million versus $76.6 million profit, with diluted EPS at -$0.11 from $0.89, highlighting the transition from one-time income to sustainable investment in pipeline advancement.